GCP
BCYC

GSA Capital Partners’s Bicycle Therapeutics BCYC Stock Holding History

GSA Capital Partners’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Buy
30,785
+3,943
+15% +$18.1K 0.01% 1599
2026
Q1 		$125K Buy
+26,842
New +$153K 0.01% 1541
2025
Q2 		– Sell
-11,952
Closed -$101K – 1751
2025
Q1 		$101K Buy
+11,952
New +$141K 0.01% 1496

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

GSA Capital Partners's BCYC Position: Q2 2026 in Review

GSA Capital Partners increased its Bicycle Therapeutics (BCYC) stake by 15% in Q2 2026, buying an estimated $18.1K and bringing the position to 30,785 shares worth $131K. The position accounts for 0.01% of the portfolio, ranked #1599.

GSA Capital Partners first reported a position in BCYC in Q1 2025 and has held it in 3 quarters since. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • GSA Capital Partners held 30,785 shares of Bicycle Therapeutics worth $131K as of Q2 2026.
  • GSA Capital Partners bought 3,943 Bicycle Therapeutics shares in Q2 2026, an estimated $18.1K.
  • Bicycle Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1599 holding.
  • GSA Capital Partners first reported a position in Bicycle Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.